Company news

Stoke Therapeutics, Inc. news in 2021

Stoke Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting

December 2, 2021

Stoke Therapeutics Announces Presentations from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting

November 18, 2021

Stoke Therapeutics to Present at Upcoming Investor Conferences in November

November 2, 2021

Stoke Therapeutics to Present at the Cantor Global Healthcare Virtual Conference

September 21, 2021

Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome

September 20, 2021

Stoke Therapeutics to Present at Upcoming Investor Conferences in August

August 2, 2021

Stoke Therapeutics to Present at the UBS Global Healthcare Virtual Conference

May 17, 2021

Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy (ADOA)

May 3, 2021

Stoke Therapeutics Announces MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in the United Kingdom

March 29, 2021

Stoke Therapeutics to Present at Upcoming Investor Conferences

March 23, 2021

Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates

March 8, 2021

Stoke Therapeutics to Present at the Barclays Global Healthcare Conference

March 3, 2021

Stoke Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 3, 2021

Decks in 2021